{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33596266",
  "DateCompleted": {
    "Year": "2021",
    "Month": "02",
    "Day": "24"
  },
  "DateRevised": {
    "Year": "2023",
    "Month": "11",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "02",
        "Day": "17"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "e1009225",
      "10.1371/journal.ppat.1009225"
    ],
    "Journal": {
      "ISSN": "1553-7374",
      "JournalIssue": {
        "Volume": "17",
        "Issue": "2",
        "PubDate": {
          "Year": "2021",
          "Month": "Feb"
        }
      },
      "Title": "PLoS pathogens",
      "ISOAbbreviation": "PLoS Pathog"
    },
    "ArticleTitle": "SARS-CoV-2 tropism, entry, replication, and propagation: Considerations for drug discovery and development.",
    "Pagination": {
      "StartPage": "e1009225",
      "MedlinePgn": "e1009225"
    },
    "Abstract": {
      "AbstractText": [
        "Since the initial report of the novel Coronavirus Disease 2019 (COVID-19) emanating from Wuhan, China, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread globally. While the effects of SARS-CoV-2 infection are not completely understood, there appears to be a wide spectrum of disease ranging from mild symptoms to severe respiratory distress, hospitalization, and mortality. There are no Food and Drug Administration (FDA)-approved treatments for COVID-19 aside from remdesivir; early efforts to identify efficacious therapeutics for COVID-19 have mainly focused on drug repurposing screens to identify compounds with antiviral activity against SARS-CoV-2 in cellular infection systems. These screens have yielded intriguing hits, but the use of nonhuman immortalized cell lines derived from non-pulmonary or gastrointestinal origins poses any number of questions in predicting the physiological and pathological relevance of these potential interventions. While our knowledge of this novel virus continues to evolve, our current understanding of the key molecular and cellular interactions involved in SARS-CoV-2 infection is discussed in order to provide a framework for developing the most appropriate in vitro toolbox to support current and future drug discovery efforts."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-7094-3344"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Genetics and Pharmacogenomics, Merck & Co., Inc., Kenilworth, New Jersey, United States of America."
          }
        ],
        "LastName": "Murgolo",
        "ForeName": "Nicholas",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America."
          }
        ],
        "LastName": "Therien",
        "ForeName": "Alex G",
        "Initials": "AG"
      },
      {
        "Identifier": [
          "0000-0002-5915-9943"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Howell",
        "ForeName": "Bonnie",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Computational and Structural Chemistry, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Klein",
        "ForeName": "Daniel",
        "Initials": "D"
      },
      {
        "Identifier": [
          "0000-0001-5469-4448"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pharmacokinetics, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Koeplinger",
        "ForeName": "Kenneth",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America."
          }
        ],
        "LastName": "Lieberman",
        "ForeName": "Linda A",
        "Initials": "LA"
      },
      {
        "Identifier": [
          "0000-0002-2155-6927"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Quantitative Biosciences, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Adam",
        "ForeName": "Gregory C",
        "Initials": "GC"
      },
      {
        "Identifier": [
          "0000-0003-4406-0235"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Flynn",
        "ForeName": "Jessica",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "McKenna",
        "ForeName": "Philip",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Exploratory Science Center, Merck & Co., Inc., Cambridge, Massachusetts, United States of America."
          }
        ],
        "LastName": "Swaminathan",
        "ForeName": "Gokul",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Discovery Biology & Translational Medicine, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Hazuda",
        "ForeName": "Daria J",
        "Initials": "DJ"
      },
      {
        "Identifier": [
          "0000-0001-5521-0206"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Infectious Diseases and Vaccines, Merck & Co., Inc., West Point, Pennsylvania, United States of America."
          }
        ],
        "LastName": "Olsen",
        "ForeName": "David B",
        "Initials": "DB"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "PLoS Pathog",
    "NlmUniqueID": "101238921",
    "ISSNLinking": "1553-7366"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EC 3.4.-",
      "NameOfSubstance": "Cathepsins"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "Serine Endopeptidases"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "TMPRSS2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.21.75",
      "NameOfSubstance": "FURIN protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.21.75",
      "NameOfSubstance": "Furin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cathepsins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Development"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Discovery"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Endocytosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Furin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Serine Endopeptidases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Viral Tropism"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Replication"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ],
  "CoiStatement": "All authors are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and may own stock or hold stock options in Merck & Co., Inc., Kenilworth, NJ, USA."
}